Research programme: matrix metalloproteinase inhibitors - Solvotrin Innovations

Drug Profile

Research programme: matrix metalloproteinase inhibitors - Solvotrin Innovations

Alternative Names: SI 1004; SI 1005

Latest Information Update: 21 Oct 2015

Price : $50

At a glance

  • Originator Solvotrin Innovations
  • Class Nitrogen compounds; Tetracyclines
  • Mechanism of Action Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone disorders; Cancer; Cardiovascular disorders; Inflammation

Most Recent Events

  • 21 Oct 2015 Preclinical trials in Bone disorders in Ireland (unspecified route)
  • 21 Oct 2015 Solvotrin has patent protection for MMP-9 inhibitors worldwide
  • 21 Oct 2015 Preclinical trials in Inflammation in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top